When "no data" is the complete and final answer

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I have written this out at length because the short version keeps being misread.

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

Written quickly, so the reasoning may be tighter than the wording.

Post #15 and I disagree about the size of the effect, not about the direction.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Taking post #15 at face value and following it one step further.

Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

One of those cases where knowing the mechanism does not help the decision.

Melanotan II is a non-selective melanocortin agonist, which is why its effects are not confined to pigmentation. The non-selectivity is the mechanism and not a side issue.

I would treat that as a working assumption and revisit it.

Post #20 is the version of this I will quote in future. One addition.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

I have separated what I observed from what I concluded, which does not always happen.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Adding a data point of agreement rather than a data point.

Answering the question post #22 raises rather than the one it answers.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

A qualification I should have led with rather than closed on.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Nicotinamide adenine dinucleotide preparations are not peptides at all and the certificate conventions are completely different. Reading one as though it were a peptide certificate produces confusion in both directions.

Narrowing post #24, because the general version has more than one answer.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

This is the version I would want a new member to read first.

Everything in post #26 holds. The case it does not cover is the one I have.

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

That is where I would start, not where I would stop.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Coming back to post #26, because the follow-up matters more than the original answer.

Dose conversions between related compounds in this subcategory are made far too casually. Structural similarity does not imply potency similarity and frequently does not imply the same receptor profile.

Adding the caveat now so it does not have to be extracted later.